{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:22:08Z","timestamp":1738819328736,"version":"3.37.0"},"reference-count":0,"publisher":"Ideggyogyaszati Szemle Journal","issue":"1-2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>A myasthenia gravis (MG) a neuromuscularis\ntranszmisszi\u00f3 zavar\u00e1val jellemzett ellenanyag-medi\u00e1lt autoimmun betegs\u00e9g,\nklinikailag k\u00f3ros izomgyenges\u00e9g, f\u00e1rad\u00e9konys\u00e1g t\u00fcneteivel manifeszt\u00e1l\u00f3dik, ami\njelentkezhet izol\u00e1ltan a szemizmokban vagy\ngeneraliz\u00e1ltan a test egy\u00e9b har\u00e1ntcs\u00edkolt\nizmaiban is (bulbaris, v\u00e9gtagi, l\u00e9gz\u0151izmok).\nA betegs\u00e9g a becsl\u00e9sek szerint haz\u00e1nkban\n1700 beteget \u00e9rint. Enyh\u00e9bb esetekben t\u00fcneti \u2013 kolin\u00e9szter\u00e1z-g\u00e1tl\u00f3 \u2013 kezel\u00e9s elegend\u0151\nlehet a betegs\u00e9g kezel\u00e9s\u00e9ben, de a betegek\nt\u00f6bbs\u00e9ge a k\u00f3rt\u00f6rt\u00e9nete sor\u00e1n hosszabb-r\u00f6videbb id\u0151tartam\u00fa immunszuppressz\u00edv kezel\u00e9sre szorul. A hagyom\u00e1nyos gy\u00f3gyszerekkel\naz esetek 60-70%-\u00e1ban \u00e9rhet\u0151 el t\u00fcnetmentes \u00e1llapot. A betegek 10-20%-a szenved\nrefrakter myastheni\u00e1ban, \u0151k a hagyom\u00e1nyos\nkezel\u00e9sre nem reag\u00e1lnak megfelel\u0151en, vagy\naz alkalmazott kezel\u00e9s mellett toler\u00e1lhatatlan\nmell\u00e9khat\u00e1sokat tapasztalnak.\nAz ut\u00f3bbi \u00e9vekben t\u00f6bb klinikai vizsg\u00e1lat\nzajlott MG-ben \u00faj, c\u00e9lzott molekul\u00e1ris ter\u00e1pi\u00e1kkal: ma m\u00e1r komplement-, FcRn- \u00e9s B-sejtg\u00e1tl\u00f3 szerek sz\u00e9les\u00edtik ter\u00e1pi\u00e1s arzen\u00e1lunkat,\n\u00e9s \u00edg\u00e9rnek izgalmas, bizony\u00edtottan hat\u00e9kony,\nviszonylag gyors hat\u00e1s\u00fa kezel\u00e9si lehet\u0151s\u00e9geket, mindenekel\u0151tt refrakter MG-ben.\nNapjainkban az MG-kezel\u00e9s c\u00e9lja a teljes\nremisszi\u00f3 el\u00e9r\u00e9se, a l\u00e9gz\u00e9si el\u00e9gtelens\u00e9ggel j\u00e1r\u00f3 myastheni\u00e1s kr\u00edzis kiv\u00e9d\u00e9se \u00e9s a\nbetegek \u00e9letmin\u0151s\u00e9g\u00e9t negat\u00edvan befoly\u00e1sol\u00f3 t\u00fcnetek megsz\u00fcntet\u00e9se. A k\u00f3rk\u00e9p ritka\nvolta, v\u00e1ltozatos lefoly\u00e1sa indokoltt\u00e1 teszi \u2013 k\u00fcl\u00f6n\u00f6sen a refrakter betegek eset\u00e9ben \u2013,\nhogy a gondoz\u00e1s az MG kezel\u00e9s\u00e9ben nagy\ngyakorlattal rendelkez\u0151, a k\u00f3rk\u00e9p ell\u00e1t\u00e1s\u00e1nak\nteljes spektrum\u00e1val b\u00edr\u00f3 neuroimmunol\u00f3giai\ncentrumokban t\u00f6rt\u00e9njen. A refrakter MG\nhat\u00e9kony kezel\u00e9s\u00e9hez elengedhetetlen, hogy\na k\u00f6zelm\u00faltban t\u00f6rzsk\u00f6nyvezett \u00faj ter\u00e1pi\u00e1k\nmiel\u0151bb el\u00e9rhet\u0151v\u00e9 v\u00e1ljanak a magyar betegek sz\u00e1m\u00e1ra is.<\/jats:p>","DOI":"10.18071\/isz.78.0027","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:25:09Z","timestamp":1738761909000},"page":"27-36","source":"Crossref","is-referenced-by-count":0,"title":["A myasthenia gravis kezel\u00e9s\u00e9nek b\u0151v\u00fcl\u0151 lehet\u0151s\u00e9gei, a c\u00e9lzott kezel\u00e9s \u00faj szeml\u00e9lete, \u00faj ter\u00e1pi\u00e1k megjelen\u00e9se a hazai gyakorlatban"],"prefix":"10.18071","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-6177","authenticated-orcid":false,"given":"Csilla","family":"R\u00f3zsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7411","published-online":{"date-parts":[[2025]]},"container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"original-title":[],"link":[{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/new-treatment-options-of-myasthenia-gravis-new-approach-to-biological-agents-reimbursement-of-new-therapies-in-hungary\/pdf-open","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:25:11Z","timestamp":1738761911000},"score":1,"resource":{"primary":{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/new-treatment-options-of-myasthenia-gravis-new-approach-to-biological-agents-reimbursement-of-new-therapies-in-hungary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.18071\/isz.78.0027","relation":{},"ISSN":["0019-1442","2498-6208"],"issn-type":[{"value":"0019-1442","type":"print"},{"value":"2498-6208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}